Literature DB >> 19540283

Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus.

Qingxia Han1, Chunlian Xu, Chunchen Wu, Wenbo Zhu, Rongge Yang, Xinwen Chen.   

Abstract

In this study, an infectious HCV monocistronic reporter virus was constructed by inserting an EGFP gene into the C-terminus of NS5A in the JFH-1 genome. A robust adaptive mutant, which could produce infectious virions as robustly as the JFH-1 wild type in Huh7.5.1 cells, was subsequently isolated by monitoring EGFP fluorescence. Full genomic sequencing revealed five amino acid substitutions, three located in the helicase domain of NS3 and two positioned in the C-terminus of NS5A. Reverse genetics studies suggested that the NS3 and NS5A mutations acted synergistically to enhance virus production capability possibly by accelerating the virion assembly efficiency but did not affect the replication competence of the adaptive reporter virus. Further analysis revealed that the M260K and T462I substitutions in NS3 and NS5A, respectively, were the key mutations. These adaptive mutations were also effective in the context of the JFH-1 genome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19540283     DOI: 10.1016/j.virusres.2009.06.005

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  40 in total

Review 1.  Hepatitis C virus: assembly and release of virus particles.

Authors:  Daniel M Jones; John McLauchlan
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

2.  A genetic interaction between the core and NS3 proteins of hepatitis C virus is essential for production of infectious virus.

Authors:  Daniel M Jones; Ali M Atoom; Xiaozhen Zhang; Shyamasundaran Kottilil; Rodney S Russell
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

3.  The acidic domain of hepatitis C virus NS4A contributes to RNA replication and virus particle assembly.

Authors:  Tung Phan; Andrew Kohlway; Peniel Dimberu; Anna Marie Pyle; Brett D Lindenbach
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

4.  Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease.

Authors:  Ye Yu; Jing-feng Jing; Xian-kun Tong; Pei-lan He; Yuan-chao Li; You-hong Hu; Wei Tang; Jian-ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2014-07-21       Impact factor: 6.150

5.  Construction of a chimeric hepatitis C virus replicon based on a strain isolated from a chronic hepatitis C patient.

Authors:  Huang Cao; Wandi Zhu; Qingxia Han; Rongjuan Pei; Xinwen Chen
Journal:  Virol Sin       Date:  2014-01-20       Impact factor: 4.327

6.  Cytosolic phospholipase A2 gamma is involved in hepatitis C virus replication and assembly.

Authors:  Song Xu; Rongjuan Pei; Min Guo; Qingxia Han; Juan Lai; Yun Wang; Chunchen Wu; Yuan Zhou; Mengji Lu; Xinwen Chen
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

Review 7.  Strategies for antiviral screening targeting early steps of virus infection.

Authors:  Tao Peng
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

8.  Conserved GXXXG- and S/T-like motifs in the transmembrane domains of NS4B protein are required for hepatitis C virus replication.

Authors:  Qingxia Han; Jason Aligo; David Manna; Kerry Belton; Sree V Chintapalli; Yoojin Hong; Randen L Patterson; Damian B van Rossum; Kouacou V Konan
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

9.  Different responses of two highly permissive cell lines upon HCV infection.

Authors:  Honghe Chen; Rongjuan Pei; Xinwen Chen
Journal:  Virol Sin       Date:  2013-06-27       Impact factor: 4.327

10.  Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype.

Authors:  Celia Perales; Nathan M Beach; Isabel Gallego; Maria Eugenia Soria; Josep Quer; Juan Ignacio Esteban; Charles Rice; Esteban Domingo; Julie Sheldon
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.